237 related articles for article (PubMed ID: 34889364)
1. Updates in chronic graft-versus-host disease.
Hamilton BK
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):648-654. PubMed ID: 34889364
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
3. GVHD Prophylaxis 2020.
Gooptu M; Antin JH
Front Immunol; 2021; 12():605726. PubMed ID: 33897681
[TBL] [Abstract][Full Text] [Related]
4. Established and Emerging Treatments of Skin GvHD.
Link-Rachner CS; Sockel K; Schuetz C
Front Immunol; 2022; 13():838494. PubMed ID: 35185931
[TBL] [Abstract][Full Text] [Related]
5. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.
Hamilton BK
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):228-235. PubMed ID: 30504315
[TBL] [Abstract][Full Text] [Related]
6. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
[TBL] [Abstract][Full Text] [Related]
7. Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.
Rozmus J
Front Immunol; 2020; 11():574569. PubMed ID: 33613511
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease management.
Mistrik M; Bojtarova E; Sopko L; Masakova L; Roziakova L; Martinka J; Batorova A
Bratisl Lek Listy; 2016; 117(7):388-96. PubMed ID: 27546540
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
Weitz M; Strahm B; Meerpohl JJ; Schmidt M; Bassler D
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009898. PubMed ID: 26666581
[TBL] [Abstract][Full Text] [Related]
11. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic approaches for the prevention and treatment of chronic GVHD.
Cutler CS; Koreth J; Ritz J
Blood; 2017 Jan; 129(1):22-29. PubMed ID: 27821505
[TBL] [Abstract][Full Text] [Related]
13. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Inamoto Y; Valdés-Sanz N; Ogawa Y; Alves M; Berchicci L; Galvin J; Greinix H; Hale GA; Horn B; Kelly D; Liu H; Rowley S; Schoemans H; Shah A; Lupo Stanghellini MT; Agrawal V; Ahmed I; Ali A; Bhatt N; Byrne M; Chhabra S; DeFilipp Z; Fahnehjelm K; Farhadfar N; Horn E; Lee C; Nathan S; Penack O; Prasad P; Rotz S; Rovó A; Yared J; Pavletic S; Basak GW; Battiwalla M; Duarte R; Savani BN; Flowers MED; Shaw BE; Petriček I
Biol Blood Marrow Transplant; 2019 Feb; 25(2):e46-e54. PubMed ID: 30481594
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
Weitz M; Strahm B; Meerpohl JJ; Bassler D
Cochrane Database Syst Rev; 2014 Feb; (2):CD009898. PubMed ID: 24569961
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
Yu Q; Wang H; Zhang L; Wei W
Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
[TBL] [Abstract][Full Text] [Related]
17. Current and future approaches for control of graft-versus-host disease.
Koreth J; Antin JH
Expert Rev Hematol; 2008 Oct; 1(1):111. PubMed ID: 20151032
[TBL] [Abstract][Full Text] [Related]
18. The management of chronic graft-versus-host disease.
Siadak M; Sullivan KM
Blood Rev; 1994 Sep; 8(3):154-60. PubMed ID: 7529605
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.
Wolff D; Steiner B; Hildebrandt G; Edinger M; Holler E
Curr Pharm Des; 2009; 15(17):1974-97. PubMed ID: 19519437
[TBL] [Abstract][Full Text] [Related]
20. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Axt L; Naumann A; Toennies J; Haen SP; Vogel W; Schneidawind D; Wirths S; Moehle R; Faul C; Kanz L; Axt S; Bethge WA
Bone Marrow Transplant; 2019 Nov; 54(11):1805-1814. PubMed ID: 31089279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
